CDEK
← All drugs Report issue

entinostat

Small moleculeexperimental

Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers. — Wikipedia

Clinical trial activity

73 trials · 49 clinical orgs · 0 marketing orgs

Phase 1
44
Phase 2
45
Phase 3
2
Phase 4
0

Earliest trial started Feb 1, 2001 (NCT00015925)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1
Mol. weight
376.42 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • carbamic acid, n-((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3- pyridinylmethyl ester
  • entinostat
  • entinostat
  • entinostat
  • entinostat
  • entinostat
  • ms 27-275
  • ms-27-275
  • ms 275
  • ms-275
  • ms-275
  • ms-275
  • ms-275
  • n-(2-aminophenyl)-4-(n-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide
  • sndx-275
  • sndx-275
  • sndx-275
  • sndx-275

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07235618Phase 2Jan 5, 2026Sun Yat-Sen University
NCT07261592Phase 1/Phase 2 (Phase 2)Dec 1, 2025Nanjing University
NCT05898828Phase 1/Phase 2 (Phase 2)Jan 3, 2024National Cancer Institute (NCI)
NCT05053971Phase 1/Phase 2 (Phase 2)Mar 11, 2022National Cancer Institute (NCI), Yale University
NCT04708470Phase 1/Phase 2 (Phase 2)Oct 5, 2021National Cancer Institute (NCI)
NCT04631029Phase 1Feb 1, 2021Johns Hopkins University, National Cancer Institute (NCI)
NCT04296942Phase 1Apr 23, 2020National Cancer Institute (NCI)
NCT03925428Phase 1Sep 1, 2019National Cancer Institute (NCI), Yale University
NCT03924245Phase 1/Phase 2 (Phase 2)Aug 15, 2019AstraZeneca, Syndax Pharmaceuticals, Vanderbilt University
NCT03760614Phase 1Jul 31, 2019Syndax Pharmaceuticals, University of Pennsylvania
NCT03978624Phase 2Jun 30, 2019University of North Carolina at Chapel Hill
NCT03838042Phase 1/Phase 2 (Phase 2)May 15, 2019German Cancer Research Center, University of Heidelberg
NCT03829930Phase 1May 1, 2019George Washington University
NCT03765229Phase 2Mar 22, 2019Syndax Pharmaceuticals, University of North Carolina at Chapel Hill
NCT03473639Phase 1Sep 30, 2018Syndax Pharmaceuticals, University of Virginia
NCT03552380Phase 2Aug 31, 2018Bristol-Myers Squibb, Hoosier Cancer Research Network, Indiana University, Syndax Pharmaceuticals
NCT03501381Phase 2May 24, 2018Clinigen, Inc., Hoosier Cancer Research Network, Indiana University, Syndax Pharmaceuticals
NCT03538171Phase 3May 15, 2018EddingPharm Oncology Co., LTD.
NCT03361800Early Phase 1 (Phase 1)Jan 22, 2018National Cancer Institute (NCI), Syndax Pharmaceuticals, University of North Carolina at Chapel Hill
NCT03211988Phase 2Dec 23, 2017Columbia University
Showing 20 of 73 trials
Page 1 / 4

Organizations

Research & Development (49)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government302632001
Syndax PharmaceuticalsFor profit301822007
Johns Hopkins UniversityAcademic/Hospital15422001
Indiana UniversityAcademic/Hospital4122008
MerckFor profit4022015
CelerionFor profit3012016
State University of New York, BuffaloAcademic/Hospital3022008
University of North Carolina at Chapel HillAcademic/Hospital3322018
Yale UniversityAcademic/Hospital3022017
Bristol-Myers SquibbFor profit2012017
ECOG-ACRIN Cancer Research GroupAcademic/Hospital2022006
EddingPharm Oncology Co., LTD.For profit2222016
Harvard UniversityAcademic/Hospital2012015
Hoosier Cancer Research NetworkAcademic/Hospital2212018
RocheFor profit2112016
SCRI Development InnovationsFor profit2012008
University of PennsylvaniaAcademic/Hospital2222017
AstraZenecaFor profit1012019
BayerFor profit1112004
Baylor UniversityAcademic/Hospital1012007
49 organizations
Page 1 / 3